Company profile
CELLDEX THERAPEUTICS, INC.
NASDAQ:CLDXBiotechnology: In Vitro & In Vivo Diagnostic Substances
Drug pipeline (10)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BARZOLVOLIMAB | phase3 | — | 14 | active |
| CDX-301 | phase2 | — | 4 | completed, terminated |
| CDX-3379 | phase2 | — | 1 | terminated |
| GLEMBATUMUMAB VEDOTIN | phase2 | — | 3 | completed, terminated |
| VARLILUMAB | phase2 | — | 2 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (43)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02335918 | phase1_2 | completed | 2015-01-01 | 2018-12-12 | Celldex Therapeutics | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors |
| NCT02837991 | phase1 | terminated | 2016-06-01 | 2018-11-16 | Celldex Therapeutics | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma |
| NCT04146129 | phase1 | completed | 2019-10-29 | 2020-04-06 | Celldex Therapeutics | A Phase 1 Study of CDX-0159 |
| NCT05031624 | phase1 | completed | 2021-08-30 | 2022-01-14 | Celldex Therapeutics | A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects |
| NCT02014909 | phase1 | completed | 2014-01-01 | 2017-05-25 | Celldex Therapeutics | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors |
FDA applications (0)
No records yet.